Aclaris Therapeutics Inc (NASDAQ: ACRS) kicked off on Tuesday, down -0.82% from the previous trading day, before settling in for the closing price of $1.22. Over the past 52 weeks, ACRS has traded in a range of $0.59-$11.12.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 74.29%. While this was happening, its average annual earnings per share was recorded 22.38%. With a float of $64.78 million, this company’s outstanding shares have now reached $70.89 million.
The extent of productivity of a business whose workforce counts for 91 workers is very important to gauge.
Aclaris Therapeutics Inc (ACRS) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Diagnostics & Research Industry. The insider ownership of Aclaris Therapeutics Inc is 9.10%, while institutional ownership is 88.62%. The most recent insider transaction that took place on Mar 04 ’24, was worth 7,500. In this transaction Director of this company bought 6,000 shares at a rate of $1.25, taking the stock ownership to the 28,863 shares. Before that another transaction happened on Mar 01 ’24, when Company’s Director bought 8,500 for $1.23, making the entire transaction worth $10,455. This insider now owns 22,863 shares in total.
Aclaris Therapeutics Inc (ACRS) Latest Financial update
In the latest quarterly report, which was put into the public domain on 12/31/2023, the organization reported -0.42 earnings per share (EPS), higher than consensus estimate (set at -0.44) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 22.38% per share during the next fiscal year.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Trading Performance Indicators
Take a look at Aclaris Therapeutics Inc’s (ACRS) current performance indicators. Last quarter, stock had a quick ratio of 4.16. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.27, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -0.82 in one year’s time.
Technical Analysis of Aclaris Therapeutics Inc (ACRS)
The latest stats from [Aclaris Therapeutics Inc, ACRS] show that its last 5-days average volume of 1.02 million was inferior to 1.48 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 58.33%. Additionally, its Average True Range was 0.06.
During the past 100 days, Aclaris Therapeutics Inc’s (ACRS) raw stochastic average was set at 57.75%, which indicates a significant increase from 43.75% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 31.11% in the past 14 days, which was lower than the 84.70% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2200, while its 200-day Moving Average is $3.6721. Now, the first resistance to watch is $1.2300. This is followed by the second major resistance level at $1.2500. The third major resistance level sits at $1.2700. If the price goes on to break the first support level at $1.1900, it is likely to go to the next support level at $1.1700. The third support level lies at $1.1500 if the price breaches the second support level.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Key Stats
The company with the Market Capitalisation of 86.22 million has total of 71,265K Shares Outstanding. Its annual sales at the moment are 31,250 K in contrast with the sum of -88,480 K annual income. Company’s last quarter sales were recorded 17,570 K and last quarter income was -1,490 K.
